文献速递神经肿瘤

甲基CpG结合蛋白2作为潜在诊断和预后标志物通过激活Wnt/β-Catenin通路促进胶质瘤进展

Methyl-CpG Binding Protein 2 as a Potential Diagnostic and Prognostic Marker Facilitates Glioma Progression Through Activation of Wnt/β-Catenin Pathway.
PubMed 文献 · World Neurosurg · 2022-12-16

本研究探讨MeCP2在胶质瘤中的作用机制,发现MeCP2在胶质瘤组织和细胞系中上调,敲低MeCP2可抑制增殖和上皮-间质转化并促进凋亡,且减弱小鼠模型体内胶质瘤生长;miR-138-5p靶向抑制MeCP2并失活Wnt/β-catenin通路,miR-138-5p/MeCP2/Wnt/β-catenin轴可能成为胶质瘤治疗新靶点。

要点

  • MeCP2在胶质瘤组织和细胞系中表达上调。
  • 敲低MeCP2抑制胶质瘤细胞增殖和上皮-间质转化,促进凋亡,并减弱小鼠模型体内胶质瘤生长。
  • miR-138-5p靶向抑制MeCP2表达,进而失活Wnt/β-catenin信号通路;miR-138-5p/MeCP2/Wnt/β-catenin轴可能成为胶质瘤治疗新靶点。

核心结论

  • miR-138-5p/MeCP2/Wnt/β-catenin信号轴可能成为胶质瘤治疗策略的新靶点。

研究设计与样本

  • 研究检测了胶质瘤组织和细胞系中MeCP2、miR-138-5p、上皮-间质转化、凋亡相关基因及Wnt/β-Catenin通路相关基因和增殖的表达。
  • 采用CCK-8法和流式细胞术评估胶质瘤细胞增殖和凋亡,双荧光素酶报告基因实验检测miR-138-5p与MeCP2的关系,并在小鼠异种移植肿瘤模型体内检测MeCP2对U87细胞的作用。

主要发现

  • MeCP2在胶质瘤组织和细胞系中上调,敲低MeCP2抑制胶质瘤细胞增殖和上皮-间质转化,促进细胞凋亡。
  • 敲低MeCP2减弱小鼠模型体内胶质瘤生长。
  • miR-138-5p通过靶向MeCP2阻碍其表达,进而失活Wnt/β-catenin信号通路。
  • 回复实验显示miR-138-5p抑制胶质瘤恶性表型,MeCP2过表达逆转miR-138-5p上调的抑制效应;MeCP2过表达促进胶质瘤发展。
  • XAV-939抑制Wnt/β-catenin信号通路可挽救miR-138-5p过表达的促进效应。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Glioma is the primary malignant tumor in the central nervous system and has high malignancy, mortality, and recurrence rates. Because of its heterogeneity and drug resistance, the blood-brain barrier, and other factors, the treatment of glioma has mainly been surgical resection combined with traditional radiotherapy and chemotherapy. However, the therapeutic effect has not been satisfactory. Methyl-CpG binding protein 2 (MeCP2) is an epigenetic regulator that has been reported to regulate the initiation and progression of glioma. However, the underlying mechanism in glioma has remained unclear. METHODS: The gene expression of MeCp2, miR-138-5p, the epithelial-mesenchymal transition, the apoptosis-related gene, and the Wnt/β-Catenin pathway-related gene and proliferation were detected by reverse transcription-quantitative polymerase chain reaction or Western blot. The cell proliferation and apoptosis of the glioma cell was assessed using the CCK-8 assay and flow cytometry assay. The relationship between miR-138-5p and MeCp2 was measured using the dual luciferase reporter assay. The effect of MeCp2 in U87 cells was examined in a xenograft tumorigenesis model in vivo. RESULTS: In our study, we found that MeCP2 was upregulated in glioma tissues and cell lines and that MeCP2 knockdown repressed cell proliferation and epithelial-mesenchymal transition but boosted cell apoptosis in glioma. Furthermore, MeCP2 knockdown attenuated in vivo glioma growth in a mice model. Mechanistically, miR-138-5p hindered the expression of MeCP2 by target MeCP2 and then inactivated the Wnt/β-catenin signaling pathway. In addition, subsequent rescue assays disclosed that miR-138-5p repressed the glioma malignant phenotype and MeCP2 overexpression reversed the inhibitory effect of miR-138-5p upregulation. Consistently, overexpression of MeCP2 elevated glioma development. However, inhibition of the Wnt/β-catenin signaling pathway with XAV-939 rescued the facilitation effect by overexpressing miR-138-5p. CONCLUSIONS: Our results have revealed that miR-138-5p/MeCP2/Wnt/β-catenin signaling might be a new target axis for glioma treatment strategies.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Huang G, Wu Y, Du Y, et al. Methyl-CpG Binding Protein 2 as a Potential Diagnostic and Prognostic Marker Facilitates Glioma Progression Through Activation of Wnt/β-Catenin Pathway. World Neurosurg. 2022. PMID: 36529430. doi:10.1016/j.wneu.2022.12.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。